GlassScriptPhysician profile
Mathew G Krista
NPI 1093779738
$2,377.68
in general payments reported to CMS, 2019-2025
30 companies · $569 in 2025
The $569 reported for 2025 was more than what 93% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $232 · 2021: $291 · 2022: $425 · 2023: $286 · 2024: $460 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $424.21 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $346.62 | 2021-2025 | |
| Lilly USA, LLC | $289.37 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $218.97 | 2020-2023 | Verquvo, Belsomra |
| Pfizer INC. | $170.86 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.12 | 2022-2025 | |
| Eisai INC. | $71.91 | 2020-2021 | |
| Nevro Corp. | $64.25 | 2022-2023 | Senza |
| Janssen Pharmaceuticals, INC | $63.59 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $61.52 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.57 | 2022 | |
| Novartis Pharmaceuticals Corporation | $53.36 | 2022-2024 | |
| Novo Nordisk INC | $46.58 | 2023-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $39.39 | 2023 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $34.55 | 2025 | Auvelity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $32.28 | 2020 | |
| Dexcom, INC. | $28.32 | 2021-2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.86 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $24.38 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.24 | 2025 | Gvoke Hypopen |
| Shire North American Group INC | $23.62 | 2019 | |
| Horizon Therapeutics Plc | $22.14 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.10 | 2024 | Xifaxan, Trulance |
| Shield Therapeutics INC | $20.56 | 2025 | |
| Esperion Therapeutics, INC. | $18.39 | 2022 | |
| Amarin Pharma, INC. | $18.07 | 2021 | |
| Exact Sciences Corporation | $15.33 | 2025 | The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $14.95 | 2025 | Zoryve |
| Amneal Pharmaceuticals LLC | $14.08 | 2025 | Unithroid |
| Genentech USA, INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Krista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.